Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis

Table 4

Adverse events reported in all patients treated with teriflunomide.

	Teriflunomide, N = 81
Patients with at least one adverse event, n (%)	66 (81.4%)
The proportion of patients with an adverse event, n (%)
Hair thinning (hair loss)	51 (62.9%)
Nail loss	17 (20.9%)
Liver dysfunctional test	12 (14.8%)
Itching	8 (9.8%)
Nausea	8 (9.8%)
Pruritus	5 (6.1%)
Dyspnea	4 (4.9%)
Diarrhea	3 (3.7%)
Paresthesia	3 (3.7%)
Headache	2 (2.5%)
Psychiatric disorder	2 (2.5%)
Mediastinitis	1 (1.2%)
Flushing	1 (1.2%)
Abdominal pain	1 (1.2%)
Urinary tract infection	1 (1.2%)
Recurrent urinary tract infection	1 (1.2%)
Dry mouth	1 (1.2%)
Eye disorder	1 (1.2%)